Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Gross product sales by Quarter
Gross product sales (before gross-to-net variable consideration deductions) ($M) ($M)
Moderna Gross product sales: $122M in Q2 2026, down 30.7% from a year earlier.
Latest, Q2 2026
122
Period ended Jun 30, 2026
Change on a year earlier
-30.7%
176 in Q2 2025
History
16 quarters
Since Q3 2022
Sources
11
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Gross-to-Net Rollforward).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gross product sales (before gross-to-net variable consideration deductions) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 122 | -30.7% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 350 | +233.3% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,053 | -7.6% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,971 | -33.5% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 176 | -7.9% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 105 | -52.7% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,140 | -68.9% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 2,964 | +22.5% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 191 | -34.8% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 222 | -87.9% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 3,662 | -24.6% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 2,420 | -22.4% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 293 | – | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2023 | Mar 31, 2023 | 1,828 | – | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 4,859 | – | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 3,120 | – | Form 10-Q (filed 2023-11-03) ↗ |
Breakdown
What makes up gross product sales
Cite this data
StockData. (2026). Moderna Gross product sales ($M), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/gtn-gross-sales
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.